Advertisement

Topics

Suzhou Alphamab to Start China Trial of Bispecific HER2 Inhibitor

00:04 EDT 17 Apr 2018 | ChinaBio Today

Suzhou Alphamab was granted CFDA approval of an IND for its leading bispecific program, a HER2 inhibitor, which will be tested in patients with HER2 positive breast and gastric cancers. According to Alphamab, KN026 showed excellent binding affinity, efficacy, safety, and PK in pre-clinical tests. Initially, the company plans to start a Phase I trial in China, followed by clinical development in the US and Japan. More details....

Share this with colleagues:

Original Article: Suzhou Alphamab to Start China Trial of Bispecific HER2 Inhibitor

NEXT ARTICLE

More From BioPortfolio on "Suzhou Alphamab to Start China Trial of Bispecific HER2 Inhibitor"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Breast Cancer
Track and monitor developments in breast cancer research and commercial development.  Follow the tabs above to read the latest global news, research, clinical trials on breast cancer and follow companies active in the development of breast cancer tr...

Clincial Trials
In a clinical trial or interventional study, participants receive specific interventions according to the research plan or protocol created by the investigators. These interventions may be medical products, such as drugs or devices; procedures; or change...